# XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

> **NCT06571734** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 29 (estimated)

## Conditions studied

- Metastatic Leiomyosarcoma
- Unresectable Leiomyosarcoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT06571734
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571734, "XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06571734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*